From Financial Modeling Prep: 2025-05-21 15:22:00

Medtronic (NYSE:MDT) reported strong fiscal Q4 earnings and revenue, exceeding expectations. The company plans to spin off its Diabetes business. Full-year fiscal 2026 guidance fell short of analyst estimates.

In Q4, Medtronic posted EPS of $1.62, surpassing the $1.58 consensus. Revenue increased 3.6% to $8.93 billion, beating the $8.82 billion forecast. Adjusted operating margin improved to 27.8%.

For fiscal 2026, Medtronic expects EPS between $5.50 and $5.60, below the Street’s $5.83 estimate. The company anticipates approximately 5% organic revenue growth.



Read more at Financial Modeling Prep:: Medtronic Beats Q4, Hikes Dividend, But 2026 Outlo…